The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma

Raul Caso,Francisco Sanchez-Vega,Kay See Tan,Brooke Mastrogiacomo,Jian Zhou,Gregory D Jones,Bastien Nguyen,Nikolaus Schultz,James G Connolly,Whitney S Brandt,Matthew J Bott,Gaetano Rocco,Daniela Molena,James M Isbell,Yuan Liu,Marty W Mayo,Prasad S Adusumilli,William D Travis,David R Jones,Gregory D. Jones,James G. Connolly,Whitney S. Brandt,Matthew J. Bott,James M. Isbell,Marty W. Mayo,Prasad S. Adusumilli,William D. Travis,David R. Jones
DOI: https://doi.org/10.1016/j.jtho.2020.08.005
IF: 20.121
2020-12-01
Journal of Thoracic Oncology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>The purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histological subtypes in lung adenocarcinoma (LUAD).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We identified 604 patients with stage I-III LUAD who underwent complete resection and targeted next-generation sequencing using the MSK-IMPACT platform. Tumors were classified according to predominant histologic subtype and grouped by architectural grade (lepidic [LEP], acinar or papillary [ACI/PAP], and micropapillary or solid [MIP/SOL]). Associations between clinicopathologic factors, genomic features, mutational signatures, and recurrence were examined within subtypes and, when appropriate, quantified using competing-risks regression, with adjustment for pathologic stage and extent of resection.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>MIP/SOL tumors had higher tumor mutational burden (<em>p</em>&lt;0.001), fraction of genome altered (<em>p</em>=0.001), copy number amplifications (<em>p</em>=0.021), rate of whole-genome doubling (<em>p</em>=0.008), and number of oncogenic pathways altered (<em>p</em>&lt;0.001), compared with LEP and ACI/PAP tumors. Across all tumors, mutational signatures attributed to APOBEC activity were associated with the highest risk of postresection recurrence: SBS2 (<em>p</em>=0.021) and SBS13 (<em>p</em>=0.005). Three oncogenic pathways (p53, Wnt, Myc) were altered with statistical significance in MIP/SOL tumors. Compared with LEP and ACI/PAP tumors, MIP/SOL tumors had a higher frequency of targetable <em>BRAF</em>-V600E mutations (<em>p</em>=0.046). Among ACI/PAP tumors, alterations in the cell cycle (<em>p</em>&lt;0.001) and PI3K (<em>p</em>=0.002) pathways were associated with recurrence; among MIP/SOL tumors, only PI3K alterations were (<em>p</em>=0.049).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>These results provide the first in-depth assessment of tumor genomic profiling of predominant LUAD histologic subtypes, their associations with recurrence, and their correlation with targetable driver alterations in patients with surgically resected LUAD.</p>
oncology,respiratory system
What problem does this paper attempt to address?